The Investigative Journal’s daily review of notable filings and actions drawn from the SEC’s EDGAR system and the Commission’s newsroom. Every item below is sourced to a public record; links point to the primary documents.
The Securities and Exchange Commission opened a new enforcement front against retail investment fraud on July 7, standing up a dedicated working group even as a wave of current reports filed during the first week of July reshuffled corporate leadership and closed a string of deals. The pairing is a useful snapshot of the market the SEC now polices: a regulator publicly recommitting to bread-and-butter investor-protection cases, and a corporate calendar producing abrupt chief-executive exits, a nine-figure brand divestiture, and settlements that close out multi-million-dollar fraud matters. This edition of SEC Watch reviews seven developments that records indicate are the most consequential, and closes with filings that may warrant deeper reporting.
1. SEC stands up a Retail Fraud Working Group
The Commission announced on July 7 (Release 2026-63) the creation of a Retail Fraud Working Group intended to concentrate Division of Enforcement staff and resources on misconduct aimed at everyday investors. According to the release, the group will target “offering frauds, pump-and-dump schemes, market manipulation, and breaches of duties to customers by investment advisers and broker dealers,” and will coordinate with regulatory partners, foreign counterparts, and the SEC’s Office of Investor Education and Assistance.
SEC Chairman Paul S. Atkins framed the initiative as “a return to the core values and principles of the enforcement program,” while Division of Enforcement Director David Woodcock said the group would focus on “generating cases, building partnerships with our regulatory counterparts, and using data and technology” to stop those targeting retail investors. The group will be led by Kate Zoladz, Deputy Director, West, and Kim Frederick, Assistant Director of the Asset Management Unit.
The announcement is notable less for any single case than for what it signals about resource allocation. Standing up a named working group with dedicated leadership is a public statement of priority, and the categories it lists — offering fraud, manipulation, and adviser breaches — map closely onto the individual actions the Commission resolved this month, several of which are covered below.
2. Advisory-firm owner faces officer-and-director bar in $2.1 million scheme
On July 1 the SEC filed proposed partial judgments (Litigation Release 26579) against David Kushner of Boca Raton, Florida, and his firm La Mancha Funding Corp. The Commission’s November 2024 complaint alleges the pair raised roughly $10.49 million by selling membership interests in a series of limited liability companies that were to fund short-term loans to borrowers including sports agents and professional athletes.
Filings indicate that Kushner and La Mancha allegedly made material misrepresentations about how investor money would be used, taking undisclosed “origination” and “broker” fees and misappropriating at least $2.14 million — funds the SEC says went toward credit-card bills, a child’s college tuition, country-club dues, a Mercedes-Benz, and a rental home in the Hamptons. Kushner and La Mancha consented to judgments, subject to court approval, that would permanently enjoin them under the antifraud provisions of the Securities Act, Exchange Act, and Investment Advisers Act, with a conduct-based injunction and an officer-and-director bar for Kushner. Monetary relief was reserved for the court.
The civil matter runs alongside a criminal one: records show Kushner previously pleaded guilty to a seven-count indictment brought by the New York County District Attorney, including five counts of second-degree grand larceny. The parallel tracks make this among the more advanced matters resolved this month, and one where allegations have hardened into at least a criminal admission.
3. Las Vegas ‘financial education’ firm settles unregistered-broker charges
A case that fits squarely within the new working group’s remit closed on July 6. The SEC obtained a final consent judgment (Litigation Release 26580) against Las Vegas–based Quest Education L.L.C., its principal Daniel Blue, and former employees David Christopher White and Keitoh Jordan Spears for allegedly acting as unregistered brokers.
According to the complaint, Quest marketed itself as an investor-education company that helped customers set up self-directed retirement accounts to hold alternative investments, but its largest revenue driver was commissions from third parties for steering customers into unregistered offerings. Between October 2019 and April 2023, records indicate, Quest solicited investments in offerings from at least eight issuers and collected roughly $2.5 million in commissions, with White and Spears each receiving more than $200,000. Without admitting the allegations, the defendants consented to permanent injunctions; Blue was additionally barred from participating in securities offerings, and Blue and Spears were each ordered to pay a civil penalty of $11,823.
The retirement-account framing is worth flagging. Self-directed IRAs are a recurring vector in retail-fraud matters because they let promoters reach savers’ tax-advantaged nest eggs, precisely the constituency the SEC’s new group says it aims to protect.
4. Texas recruiter barred over $56 million real-estate Ponzi
On July 2 the SEC issued an administrative order (Release 34-105842) barring Margaret Sanders and her firm, Sanders Family Office, LLC, from association with brokers, dealers, and investment advisers. The order follows a June 24 complaint (Litigation Release 26571) and a final judgment entered June 25 in the Western District of Texas.
The Commission’s findings state that from August 2020 to March 2023, Sanders — a 66-year-old Boerne, Texas resident — and her firm acted as unregistered brokers by recruiting and managing a network of sales agents who solicited investments in Wells Real Estate Investment LLC. That entity, the SEC alleges, operated a Ponzi scheme that raised at least $56 million from roughly 660 investors. Sanders and her firm are said to have raised about $40 million from some 600 investors and received approximately $2.98 million in transaction-based commissions, despite never being registered or licensed to sell securities. Sanders consented to the entry of the order.
Because the underlying Wells Real Estate matter remains a live thread, the Sanders resolution reads less like a conclusion than a waypoint. TIJ notes that the principals of the underlying offering are the more significant potential subjects, and this order does not resolve their exposure.
5. Coty to exit Gucci Beauty in roughly $400 million settlement with Kering
Turning from enforcement to corporate disclosure, Coty Inc. disclosed in a July 7 Form 8-K that it had entered a License Termination and Transition Agreement with Kering and its Gucci subsidiaries. The agreement ends Coty’s long-running license to manufacture and sell Gucci-branded beauty products — a relationship dating to 2006 — on June 30, 2027, one year ahead of schedule.
Under the terms disclosed, Coty will receive aggregate consideration of approximately $400 million: $250 million in cash on signing and an additional $150 million (subject to a potential holdback of up to $30 million) payable by September 30, 2027. The filing states the proceeds are intended to reduce debt and reinvest in Coty’s core fragrance and beauty brands. Notably, the parties also agreed to a mutual resolution of all pending litigation tied to the license — a detail that turns a commercial wind-down into a legal cease-fire between two major beauty houses.
6. Executive shake-ups at Genworth and ARS Pharmaceuticals
Two current reports filed July 7 underscored how quickly leadership can change. Genworth Financial reported that President and CEO Thomas J. McInerney is taking a temporary leave of absence to focus on his health, with Chief Financial Officer Jerome T. Upton, 62, named interim president and CEO effective the same day. The filing frames the move as temporary and cites no disagreement, but investors will watch for updates on duration and any impact on the insurer’s long-term-care strategy.
Separately, ARS Pharmaceuticals disclosed that its board appointed President Donn Casale as chief executive effective immediately, replacing Richard Lowenthal, who the company said was “notified on July 6, 2026 that his employment was being terminated without cause, effective immediately.” Abrupt, same-day, without-cause terminations at the CEO level are relatively uncommon and often precede additional disclosure; the language here is spare, and the filing offers no stated reason for the change.
7. Scotts Miracle-Gro closes the Hagedorn era with a $17.4 million exit package
The Scotts Miracle-Gro Company disclosed in a July 1 Form 8-K that Nathan E. Baxter, 53, had been named president and CEO effective June 26, succeeding James Hagedorn, who had led the company since 2001 and chaired the board since 2003. Hagedorn resigned from the board, and Lead Independent Director Peter Shumlin was elected chairman.
The compensation detail is the story for governance watchers. In lieu of a lump-sum severance equal to three times salary and bonus, the filing states Hagedorn will receive $17.4 million (reduced by his accrued pension benefit) paid over twelve months, plus $500,000 toward operating an aircraft he owns, $150,000 in administrative support, and $3.6 million tied to non-compete and non-solicitation covenants payable over three years. The package is fully disclosed and consistent with a pre-existing 2013 severance agreement, but its size and unusual perquisites make it a candidate for scrutiny in the company’s next proxy statement.
Filings that may warrant deeper TIJ investigation
Several items merit follow-up beyond today’s digest. Clarivate Plc disclosed on July 6 an agreement to sell its Life Sciences and Healthcare business to an affiliate of the private-equity firm Altaris, LLC; the filing furnishes a press release but leaves valuation and post-sale strategy to be examined as the deal documents and any subsequent 10-Q disclosures emerge. The ARS Pharmaceuticals termination “without cause,” described above, is the kind of event that frequently generates amended filings or separation-agreement exhibits worth tracking.
On the enforcement side, the June 25 settled action against California trader Mingran Wang for an alleged “spoofing” scheme that generated more than $1.3 million (Litigation Release 26574) proceeds in parallel with criminal charges from the Department of Justice, and the criminal docket may surface facts the civil settlement did not. Finally, the SEC’s July 1 market-statistics release (2026-61) pointing to an increase in IPOs and proceeds raised bears watching against the disclosure-quality questions that tend to accompany new-issuance booms — the exact terrain the new Retail Fraud Working Group says it intends to patrol.
TIJ will continue to monitor these dockets and filings. As always, allegations described in SEC complaints are not findings of liability unless a court or the Commission has entered judgment; where defendants have settled, they have generally done so without admitting or denying the allegations, and pending matters remain subject to change.
Image: U.S. Securities and Exchange Commission headquarters, Washington, D.C. Photo by Wikimedia Commons user AgnosticPreachersKid, licensed under CC BY-SA 3.0. Sources: SEC EDGAR and the SEC newsroom, linked inline. Reporting by Eduardo Bacci for The Investigative Journal.